| Ms Donna M Deascentis, MSE, LMHC, NCC | |
|
174 Bellevue Ave, Suite 306b, Newport, RI 02840-3582 | |
| (401) 450-2704 | |
| (401) 846-1811 |
| Full Name | Ms Donna M Deascentis |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 174 Bellevue Ave, Newport, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467660340 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | MHC00482 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Donna M Deascentis, MSE, LMHC, NCC 174 Bellevue Ave, Suite 306b, Newport, RI 02840 Ph: (401) 450-2704 | Ms Donna M Deascentis, MSE, LMHC, NCC 174 Bellevue Ave, Suite 306b, Newport, RI 02840-3582 Ph: (401) 450-2704 |
News Archive
The American Academy of Dermatology will present the 2010 Gold Triangle Awards during its 68th Annual Meeting in Miami Beach in early March 2010. Promius Pharma, LLC is one of 49 winners being recognized for excellence in furthering public understanding of dermatologic issues and encouraging healthy behavior in the care of skin, hair and nails.
Today BioGaia has signed an agreement with Ferozsons Laboratories Limited, for the exclusive rights to sell BioGaia's probiotic drops and tablets in Pakistan. The products will be sold under the BioGaia brand and launch is planned to 2013.
As diagnostic imaging and radiation treatment technologies both become more capable and precise, physicians using them face an increasingly difficult task: how to transfer information from the diagnostic systems to the treatment planning systems.
Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.
› Verified 7 days ago
Mrs. Elizabeth J Hayes, MA,LMHC,LCDP Counselor Medicare: Not Enrolled in Medicare Practice Location: Codac Inc, 93 Thames St, Newport, RI 02840 Phone: 401-846-4150 | |
Bennae Emon Davis, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 54 Malbone Rd, Newport, RI 02840 Phone: 404-838-8770 | |
Ms. Katherine Mary Finnegan-walker, LICSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 15 Burnside Ave Apt 1, Newport, RI 02840 Phone: 401-842-0582 | |
Mr. Kenneth David Monroe, Counselor Medicare: Not Enrolled in Medicare Practice Location: 220 Broadway, Newport, RI 02840 Phone: 401-225-9796 | |
Jacquelene Henderson, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1341 West Main Road, Suite 16, Newport, RI 02840 Phone: 401-862-0190 | |
Ms. Marcia D House, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4 Calvert St, Newport, RI 02840 Phone: 401-849-9260 | |
Dr. Victoria Manion Fleming, PHD, LMHC, LCPC, NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 360 Broadway, Newport, RI 02840 Phone: 860-999-1257 |